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Choline in Pediatric Depression
Frank P MacMaster*, Vivek Kusumakar
ABSTRACT: Purpose of Study: The prefrontal cortex has been previously implicated in the
neuropathology of major depressive disorder (MDD). Hence, we used proton magnetic resonance
spectroscopy (1H-MRS) to examine choline levels in the prefrontal cortex of youth with major
depression. Basic Procedures:  Twelve age- and sex-matched case-control pairs were examined
(age range 10 to 18 years, 7 females and 5 males in each group). All subjects were treatment naive
at the time of the scan. A long echo 1H-MRS scan was acquired from the right prefrontal cortex
(4cc) in all subjects. Main Findings: Right prefrontal Choline/Creatine ratios were elevated in the
youth with mood disorders (F1, 11 = 10.741, p = 0.007) as compared with healthy controls.
Principal Conclusions: These findings suggest that prefrontal cytosolic choline may be increased
in youth with MDD in comparison with healthy controls. This is consistent with reported findings
in both adults and adolescents and suggests that MDD in youth is associated with alterations in
choline metabolism in the prefrontal cortex.
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INTRODUCTION
Numerous proton magnetic resonance spectroscopy
(1H-MRS) studies have linked cytosolic choline levels
to the neuropathology of mood disorders (1-7).
Increases in choline in depressed subjects have been
noted in adults (1,3) and in pediatric samples (4,5).
Conversely, two studies demonstrated reduction in
choline (6,7). Auer and others (8) did not note any
significant difference in choline levels in the cingulate
in their study of MDD subjects and controls. The
choline resonance derived by 1H-MRS arises mainly
from phosphocholine and glycerophosphocholine
(9,10).
Children and adolescents have been relatively
understudied with regard to the neurobiology of mood
disorders. This is despite the fact that the prevalence of
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depression increases during adolescence, rising from
1% up to adult levels (6-8%). Mood disorders in youth
are associated with impairment in social, family and
academic functioning, are highly predictive of future
episodes and are significantly related to suicide (11).
Despite the prevalence and outcomes associated with
the mood disorders, there is a paucity of information
about the etiology. Hence, studies of children and
adolescents are necessary in order to determine if
abnormalities noted in adult populations occur across
the life span, how early they present during
development, and whether they can be used as
predictors for future risk of developing depression.
Studies early in the course of an illness also avoid the
potential confounds of illness chronicity,
hospitalization and long-term medication use. This
study endeavors to uncover neurobiological correlates
of juvenile depression. Based on the adult literature (1-
3,6,7) and the reports on pediatric depression (4,5), we
hypothesized that youth with MDD and those without
psychiatric illness will demonstrate differences with
regard to cytosolic choline in the prefrontal cortex.Choline in Pediatric Depression 25
METHODS
Subjects
Subjects were recruited through either of two
methods: (1) advertisements, or (2) as participants in
clinical treatment (combined pharmacological and
psychotherapy) programs.  All subjects and one of their
parents/guardians signed informed consents for the
study after a full explanation of the procedures in
accordance with the Research Ethics Board approval
provided by the IWK Health Centre. Each subject
completed the Children's Depression Rating Scale
(CDRS) (mood disorder group mean = 66.083 +
14.042) at the time of scan. Diagnosis based on Kiddie-
Schedule for Affective Disorders and Schizophrenia-
Present and Lifetime Version (K-SADS-PL) criteria
were established by a board-certified psychiatrist
(primarily VK). Twelve subjects (5 males, 7 females)
aged 10 to 18 years old with MDD and twelve age and
sex-matched healthy controls participated in this study.
All subjects were treatment naive at the time of the
scan. All data is reported as mean +/- standard deviation
unless otherwise specified. Exclusion criteria for
participation in this study included a history of
neurological illness, serious medical illness,
claustrophobia, age greater than 18 years, or the
presence of a ferrous implant or pacemaker. 
Magnetic Resonance Spectroscopy Procedures
Scans were conducted at the Queen Elizabeth II
Health Sciences Centre using a Siemens Magnetom
Vision 1.5 Tesla scanner. Multi-slice scout images
(axial, coronal and sagittal planes) were used for voxel
orientation. Special care was taken to ensure adequate
coverage of the right prefrontal gray matter by the
voxel. A long echo proton magnetic resonance
spectroscopic imaging (1H-MRS) procedure was used
to acquire spectra from the sample. Parameters were as
follows: TE = 135 ms, TR = 1500 ms, acquisitions 256,
voxel = 4cc, time = 8 minutes (see Figure 1 for sample
spectra). A trained MRS analyst (FPM) analyzed data in
a blind manner. MRS metabolites that can be visualized
with this technique are N-acetyl-aspartate (NAA,
2.02ppm), creatine/phosphocreatine (Cr, 3.03ppm) and
choline compounds (Cho, 3.20ppm). Following a
convention that minimizes variations in the magnetic
field homogeneity, metabolite concentrations are
expressed as ratios of peak areas (i.e. NAA/Cr, Cho/Cr).
Statistical Analysis
A repeated measures ANOVA was used to determine
group differences in choline levels between MDD
patients and healthy age and sex-matched controls. We
expected that close age and sex- matching allows for a
reduction in the potential confounds of sex and age on
the data set. Correlations (two-tailed) between
metabolites and age and, in the psychiatric group,
depressive symptom severity were also conducted.
RESULTS
The two groups did not differ with regard to age
(control group mean = 14.917 years + 2.575, mood
disorder group mean = 14.750 years + 2.454, t11 =
1.000, p = 0.339). Cho/Cr ratios were increased (39%)
in right prefrontal cortex in the MDD group as
compared to matched healthy controls (control mean =
0.782 + 0.170, MDD group mean = 1.088 + 0.368, F1,
11 = 10.741, p = 0.007). Right prefrontal NAA/Cr did
not differ between the healthy controls and MDD
subjects (control mean = 2.135 + 0.378, MDD group
mean = 2.408 + 0.490, F1, 11 = 2.702, p = 0.129). In the
control group, Cho/Cr demonstrated a trend for inverse
correlation with age in years (r = -0.516, p = 0.087) but
not in the MDD group (r = 0.343, p = 0.284). In the
MDD group, Cho/Cr demonstrated a weak trend for
positive correlation with CDRS symptom severity score
(r = 0.480, p = 0.117)
DISCUSSION
We report a significant increase in Cho/Cr in youth
with MDD as compared to age- and sex-matched
healthy controls in a voxel located in the right prefrontal
cortex. This finding is consistent with previous reports
of abnormalities in the choline resonance in mood
disorders (1-7). Choline acts as a precursor of the
neurotransmitter acetylcholine and the membrane
lipids, phosphatidylcholine and sphingomyelin. As
these lipids are typically bound in the membrane, they
contribute little to the MRS choline resonance, while
the cytosolic choline compounds, such as
glycerophosphocholine (GPC) and phosphocholine
(PC) contribute as much as 50% to the choline signal.
Free choline, acetylcholine, and cytidine diphosphate
choline make smaller contributions to the resonance
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Figure 1. Voxel placement and spectra from a healthy control and a
depressed adolescent. NAA = N-Acetyl-Aspartate, Cr =
Creatine/Phosphocreatine, Cho = Choline compounds.26 McGill Journal of Medicine 2006
(12-14). Based on this information, changes in the
choline resonance are thought to reflect changes in GPC
and/or PC. 
It has been postulated that changes in the choline
resonance may be reflective of changes in local
neuronal metabolism. These changes in metabolism
may be required for the incorporation of cytosolic
choline compounds into phospholipids. A previous
study has shown changes in PET measures of
metabolism to be inversely correlated with the 1H-MRS
choline resonance (15). Steingard and others (4) have
also found increases in prefrontal choline in adolescent
depression.  This is an interesting finding given that the
prefrontal cortex has been repeatedly implicated in
metabolic neuroimaging studies in mood disorders
(16,17).
It is also a possibility that the choline increase
demonstrated in the prefrontal cortex of MDD subjects
as compared to the controls in this study may reflect
differences in glucocorticoid activity. One of the most-
replicated findings in biological psychiatry has been the
alteration in the endocrine system in mood disorders.
Many mood disorder patients demonstrate
hypothalamic-pituitary-adrenal (HPA) axis over
activation (18). In conditions that result in excess
glucocorticoids, such as Graves disease, Bhatara and
others (19) have observed a 32% reduction in choline.
In animal models, orally administered cortisol also
reduces Cho/Cr levels (20). Glucocorticoids likely
adversely affect phosphatidylcholine (Ptd-Cho)
metabolism in the brain by inhibiting the activity of
enzymes such as phospholipase A2 and C (21). Ptd-Cho
plays a role in the second messenger system and signal
transduction, as it is a source for diaglycerol (22-25). As
an increase in choline has been shown in this report, a
primary role for glucocorticoids in this instance may be
unlikely.
In emotional processing, the amygdala is required to
apply emotional "tone" to a stimulus while the
prefrontal cortex provides inhibitory modulation (26).
Prefrontal cortex modulation of amygdala function may
be diminished in mood disorders, and hence a lack of
control over negative cognition may result. Should
critical prefrontal inputs to the amygdala be rendered
impotent, the inhibitory control of the prefrontal cortex
would be lost. Most likely, however, is that the
emotional homeostatic mechanisms of both the
prefrontal and limbic regions are dysfunctional in mood
disorders (27).
Previous work has demonstrated that the prefrontal
choline resonance decreases with increasing age in
healthy children and adults (28). In our study, only the
Cho/Cr levels in controls were inversely correlated with
age in years.  This was not the case for our MDD
subjects. As changes in the choline resonance during
childhood and adolescence are typically thought to
reflect changes in brain development, the lack of a
correlation in the mood disorder sample may be
indicative of a differential developmental trajectory for
these subjects. Alternatively, the change in choline may
be wrought by changes in metabolism, signal
transduction, or glucocorticoids.  These secondary
factors may be obscuring the typical developmental
trend in choline resonance. 
The principle limitations of this study are the small
sample size and the heterogeneity of clinical
presentation of the MDD group. A further limitation of
this study is the lack of absolute quantification of the
prefrontal metabolites. However, absolute
quantifications are themselves subject to magnetic
inhomogeneities and partial volume effects within the
region of interest. The use of ratios minimizes the error
introduced by variable tissue composition and
instrumental instability while allowing the evaluation of
relative alterations in metabolites. Further experiments
are required to elucidate the exact mechanism of the
increase in the Cho/Cr peaks and its relation to
depressive symptomotology. 
We report a significant increase in Cho/Cr in youth
with MDD as compared to age- and sex-matched
healthy controls in a voxel located in the right prefrontal
cortex. This fits with previous studies of cytosolic
choline in mood disorders. This increase in the Cho/Cr
ratio may be the result of reductions in metabolism in
the prefrontal cortex.
ACKNOWLEGEMENTS
The Theodore and Vada Stanley Foundation and the
Nova Scotia Health Research Foundation supported this
project.
REFERENCES
REFERENCES
1. Charles HC, Lazeyras F, Krishnan KR, Boyko OB, Payne M,
Moore D: Brain choline in depression: in vivo detection of
potential pharmacodynamic effects of antidepressant therapy
using hydrogen localized spectroscopy. Prog
Neuropsychopharmacol Biol Psychiatry 1994; 18:1121-7
2. Hamakawa H, Kato T, Murashita J, Kato N: Quantitative proton
magnetic resonance spectroscopy of the basal ganglia in patients
with affective disorders. Eur Arch Psychiatry Clin Neurosci
1998; 248: 53-8.
3. Moore CM, Breeze JL, Gruber SA, Babb SM, Frederick BB,
Villafuerte RA, Stoll AL, Hennen J, Yurgelun-Todd DA, Cohen
BM, Renshaw PF: Choline, myo-inositol and mood in bipolar
disorder: a proton magnetic resonance spectroscopic imaging
study of the anterior cingulate cortex. Bipolar Disord 2000;
2:207-16.
4. Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore
CM, Vakili K, Young AD, Katic A, Beardslee WR, Renshaw PF:
Increased orbitofrontal cortex levels of choline in depressedCholine in Pediatric Depression 27
adolescents as detected by in vivo proton magnetic resonance
spectroscopy. Biol Psychiatry 2000; 48: 1053-61.
5. Rosenberg DR, Paulson LD Seraji-Bozorgzad N, Wilds IB,
Stewart CM, Moore, GJ Brain: Chemistry in pediatric
depression. Biol Psychiatry 2000; 47:95S.
6. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen
JD, Moore CM, Yurgelun-Todd DA, Bonello CM, Pillay SS,
Rothschild AJ, Nierenberg AA, Rosenbaum JF, Cohen BM:
Basal ganglia choline levels in depression and response to
fluoxetine treatment: an in vivo proton magnetic resonance
spectroscopy study. Biol Psychiatry 1997; 41: 837-43.
7. Ende G, Braus DF, Walter S, Weber-Fahr W, Henn FA: The
hippocampus in patients treated with electroconvulsive therapy:
a proton magnetic resonance spectroscopic imaging study. Arch
Gen Psychiatry 2000; 57:937-43.
8. Auer DP, Kraft E, Lipinski B, Schill J, Holsboer F: Reduced
glutamate in the anterior cingulate cortex in depression: an in
vivo proton magnetic resonance spectroscopy study. Biol
Psychiatry 2000; 47: 305-13. 
9. Barker PB, Breiter SN, Soher BJ, Chatham JC, Forder JR,
Samphilipo MA, Magee CA, Anderson JH: Quantitative proton
spectroscopy of canine brain: in vivo and in vitro correlations.
Magn Reson Med 1994; 32:157-63. 
10. Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D,
McBride D, Jenden A: In vivo 1H MRS choline: correlation
with in vitro chemistry/histology. Life Sci 1996; 58:1929-35. 
11. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J,
Dahl RE, Perel J, Nelson B: Childhood and adolescent
depression: a review of the past 10 years. Part I. J Am Acad
Child Adolesc Psychiatry 1996; 35(11): 1427-39.
12. Klein J, Gonzalez R, Koppen A, Loffelholz K: Free choline and
choline metabolites in rat brain and body fluids: sensitive
determination and implications for choline supply to the brain.
Neurochem Int 1993; 22:293-300.
13. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W,
Sauter R: Localized proton NMR spectroscopy in different
regions of the human brain in vivo: relaxation times and
concentrations of cerebral metabolites. Magn Reson Med 1989;
11: 47-63.
14. Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J:
Absolute concentrations of metabolites in the adult human brain
in vivo: quantification of localized proton MR spectra.
Radiology 1993; 187: 219-27.
15. Duc CO, Weber AH, Trabesinger AH, Meier D, Boesiger P:
Recycling the cholines. Int Soc Magn Reson Med 1997; 6:1210.
16. Kennedy SH, Javanmard M, Vaccarino FJ: A review of
functional neuroimaging in mood disorders: positron emission
tomography and depression. Can J Psychiatry 1997; 42: 467-75.
17. Soares JC, Mann JJ: The functional neuroanatomy of mood
disorders. J Psychiatr Res 1997; 31:393-492.
18. Nemeroff CB: The neurobiology of depression. Sci Am 1998;
278: 42-9.
19. Bhatara VS, Tripathi RP, Sankar R, Gupta A, Khushu S: Frontal
lobe proton magnetic-resonance spectroscopy in Graves'
disease: a pilot study. Psychoneuroendocrinology 1998; 23: 605-
12.
20. Michaelis T., Ohl F., Fuchs E., Frahm J: Brain metabolite
alterations after oral cortisol: a proton MRS study of tree
shrews.  In Int Soc Magn Reson Med Seventh Scientific
Meeting and Exhibition, Philadelphia PA; 1999
21. Khiat A, Bard C, Lacroix A, Boulanger Y: Recovery of the brain
choline level in treated Cushing's patients as monitored by
proton magnetic resonance spectroscopy. Brain Res 2000;
862:301-7.
22. Exton JH:  Hormonal regulation of phosphatidylcholine
breakdown. Adv Second Messenger Phosphoprotein Res 1990;
24:152-7.
23. Exton JH: Phosphatidylcholine breakdown and signal
transduction. Biochem Biophys Acta 1994; 1212: 26-42.
24. Loffelholz K: Receptor regulation of choline phospholipid
hydrolysis. A novel source of diacylglycerol and phosphatidic
acid. Biochem Pharmacol 1989; 38: 1543-49.
25. Zeisel SH: Choline phospholipids: signal transduction and
carcinogenesis. FASEB J 1993; 7: 551-7.
26. MacMaster FP: Khan SC, Gates L, Kutcher SP, Kusumakar V.
Prefrontal modulation of limbic activation during an emotional
functional magnetic resonance imaging task. Brain and
Cognition 2001; 47: 100-103.
27. Kusumakar V, MacMaster FP, Schmidt M, Khan SC: Frontal-
limbic morphology in early onset depression. Biol Psychiatry
Suppl 2001; 49: 96S.
28. Hashimoto T, Tayama M, Miyazaki M, Fujii E, Harada M,
Miyoshi H, Tanouchi M, Kuroda Y: Developmental brain
changes investigated with proton magnetic resonance
spectroscopy. Dev Med Child Neurol 1995; 37: 398-405.
Vol. 9 No. 1
Frank P. MacMaster is a doctoral candidate in anatomy at Dalhousie University. His thesis is focused on potential
diagnostic biomarkers in pediatric psychiatric illness. Mr. MacMaster has a B.A. in psychology and an M.Sc. in
Anatomy & Neurobiology (Neuroscience). Mr. MacMaster uses brain-imaging technologies to study the pediatric
brain in vivo. 